Metabolomic Biomarkers In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Metabolomics is the comprehensive analysis of small molecule metabolites (<1500 Da) in biological systems. In neurodegenerative diseases, metabolomic biomarkers provide functional readouts of metabolic dysregulation, offering insights into disease mechanisms, diagnosis, and treatment response. The metabolome reflects the combined influence of genetics, environment, and disease.
- Mitochondrial dysfunction: Reduced ATP production
- Glycolysis alterations: Shifts in glucose metabolism
- Ketone body metabolism: Altered utilization
- Neurotransmitter precursors: Tryptophan, tyrosine pathways
- Glutamate toxicity: Excitotoxicity markers
- Sulfur amino acids: Methionine, cysteine alterations
- Phospholipids: Membrane integrity
- Sphingolipids: Ceramide, gangliosides
- Cholesterol: Myelin, membrane composition
- Fatty acids: β-oxidation, inflammation
- Purine metabolism: Uric acid, adenosine
- Pyrimidine metabolism: Altered in disease
| Metabolite |
Disease |
Direction |
Utility |
| Lactate |
AD, PD |
↑ |
Mitochondrial dysfunction |
| Pyruvate |
AD |
↑/↓ |
Glycolysis status |
| ATP/ADP ratio |
AD, PD |
↓ |
Energy failure |
| Ketone bodies |
AD |
↑ |
Metabolic compensation |
| Metabolite |
Disease |
Direction |
Utility |
| Glutamate |
ALS, AD |
↑ |
Excitotoxicity |
| GABA |
PD, AD |
↓ |
Inhibition loss |
| Tryptophan |
AD, PD |
↓ |
Neuroinflammation |
| Kynurenine |
AD, PD |
↑ |
Neurotoxicity |
| Serotonin |
PD, AD |
↓ |
Mood, sleep |
| Metabolite |
Disease |
Direction |
Utility |
| Sphingomyelin |
AD |
↓ |
Myelin breakdown |
| Ceramides |
AD, PD |
↑ |
Apoptosis |
| Phosphatidylcholines |
AD |
↓ |
Membrane integrity |
| 24S-Hydroxycholesterol |
AD |
↑ |
Brain cholesterol |
| Metabolite |
Disease |
Direction |
Utility |
| Arachidonic acid |
AD, PD |
↑ |
Inflammation |
| Prostaglandins |
AD, PD |
↑ |
Inflammation |
| Resolvins |
AD, PD |
↓ |
Resolution failure |
| Disease |
Panel |
Accuracy |
Notes |
| AD |
Acylcarnitines, amino acids, lipids |
75-85% |
Multi-analyte |
| PD |
Urate, amino acids |
70-80% |
Early detection |
| ALS |
Amino acids, lipids |
75-85% |
Exclude mimics |
- Metabolomic changes correlate with progression
- May predict rate of decline
- Useful for clinical trials
- Metabolic effects of medications
- Nutritional intervention monitoring
- Lifestyle intervention effects
- Blood: Plasma, serum (most common)
- CSF: More brain-specific
- Urine: Non-invasive, but less specific
| Platform |
Application |
Strengths |
| NMR |
Broad profiling |
Reproducible, minimal prep |
| LC-MS/MS |
Targeted |
Sensitive, specific |
| GC-MS |
Volatiles |
Excellent for small molecules |
| CE-MS |
Polar metabolites |
High resolution |
- Untargeted vs targeted approaches
- Machine learning for pattern recognition
- Pathway analysis
- Early changes: Decreased phosphatidylcholines, increased ceramides
- Progression: Amino acid alterations, energy failure markers
- ApoE effect: Metabolomic differences by genotype
- Urate: Lower levels associated with risk
- Lipids: Sphingolipid alterations
- Gut metabolome: α-synuclein correlates
- Creatine: Lower in patients
- Lipids: Altered phospholipid metabolism
- Amino acids: Glutamate elevated
- Creatine: Decreased
- Lipids: Altered fatty acid metabolism
- Energy: Impaired glycolysis
¶ Advantages and Limitations
- Functional readouts
- Reflect real-time physiology
- Non-invasive sampling
- Cost-effective
- Variability with diet, fasting
- Peripheral vs CNS disconnect
- Standardization challenges
- Multiple testing burden
- Ketogenic diet: Alters metabolome
- Metformin: Improves insulin sensitivity
- Creatine supplementation: Energy support
- Track metabolic effects
- Optimize dosing
- Predict response
The study of Metabolomic Biomarkers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1]Trushina E, et al. (2024). Metabolomics in Alzheimer's Disease. Alzheimer's & Dementia.
- [2]Johri A, et al. (2023). Metabolomics in Parkinson's Disease. Movement Disorders.
- [3]Blasco H, et al. (2024). Metabolomics in ALS. Neurology.
- [4]Kaddurah-Daouk R, et al. (2023). Metabolic Networks in AD. Molecular Psychiatry.
- [5]Pennington CA, et al. (2024). Lipid Biomarkers in Neurodegeneration. Nature Reviews Neurology.
- [6]Lawton KA, et al. (2023). Plasma Metabolomics in AD. Journal of Alzheimer's Disease.
- [7]Trezzi JP, et al. (2024). Metabolomics for Drug Development. Pharmacological Reviews.
- [8]Milanesi R, et al. (2023). Biomarkers of Energy Metabolism. Brain Research.